

DAFTAR PUSTAKA

- Abera W, Cheneke W, Abebe G, 2016. Incidence of antituberculosis-drug-induced hepatotoxicity and associated risk factors among tuberculosis patients in Dawro Zone, South Ethiopia: A cohort study. **Int J Mycobacteriology**: 5(1):14–20.
- Annisa R, Fauzi Z A, Fridayanti, 2015. Perbedaan Kadar Sgpt Pada Pasien Tuberkulosis Paru Sebelum dan Sesudah Fase Intensif Di Poliklinik Paru Rsud Arifin Achmad Pekanbaru. **JOM FK**: 2(2): 1-10.
- Govindan N, 2011. Angka Kejadian Hepatotoksisitas pada Penderita Tuberkulosis Paru Pengguna Obat Anti Tuberkulosis Lini Pertama Di RSUP Haji Adam Malik Tahun 2010. **Medan: Universitas Sumatera Utara**: 2011;2(2)1–2.
- Akshata J.S., Swapna R., Chakraborty A., Somashekar M., Buggi S., 2015. Hypothyroidism in MDR-TB treatment – Rare occurrence but a major concern. **Egyptian Journal of Chest Diseases and Tuberculosis**: 64, 671–674.
- Ali A, Belachew T, Yami A, Ayen W. Anti-Tuberculosis Drug Induced Hepatotoxicity among TB / HIV Co-Infected Patients at Jimma University Hospital, Ethiopia : **Nested Case-Control Study**. PloS One. 2013;8(5):1–8.
- Andries A I.P, Das M., Khan S., Paryani R., Desai C., Dalal A., Mansoor H., Verma R., Fernandes D., Sotgiu G., Migliori G.B., Saranchuk P, 2013. High rate of hypothyroidism in multidrug-resistant tuberculosis patients co-infected with HIV in Mumbai, India. **PloS one**:
- Argyaki, A. *et al.*, 2018. 生物用) HHS Public Access' *IEEE Summer Topicals Meeting Series, SUM 2015*, 10(1), pp. 1–13.
- Basu, S., Orenstein, E. and Galvani, A. P., 2008. The Theoretical Influence of Immunity between Strain Groups on the Progression of Drug-Resistant Tuberculosis Epidemics, **The Journal of Infectious Diseases**: 198(10), pp. 1502–1513.
- B.E. Senousy, S.I. Belal, P.V. Draganov, Hepatotoxic effects of therapies for tuberculosis, **Nat. Rev. Gastroenterol. Hepatol.** 7 (2010) 543–556.
- Berning S, Madsen L, Iseman M, et al. Long-term safety of ofloxacin and ciprofloxacin in the treatment of mycobacterial infections. **Am J Respir Crit Care Med** 1995; 151: 2006–2009
- Bleibel W, Kim S, Silva KD, Lemmer ER. Drug-Induced Liver Injury: Review Article. **Springer Sci + Bus Media inc** 2007;52:2463–2471.
- (CDC), C. for D. C. and P. 2017. **Reported Tuberculosis in the United States**. US Department

of Health and Human Services.

- Cambau, E., Sougakoff, W. and Jarlier, V. 1994. Amplification and nucleotide sequence of the quinolone resistance-determining region in the *gyrA* gene of mycobacteria, **FEMS Microbiology Letters**: 116(1), pp. 49–54.
- Cambau, E. *et al.*, 1994. Selection of a *gyrA* mutant of mycobacterium tuberculosis resistant to fluoroquinolones during treatment with ofloxacin. **Journal of Infectious Diseases**. 170(2), pp. 479–483
- Chang, C. Y. and Schiano, T. D. 2007. Review article: Drug hepatotoxicity, **Alimentary Pharmacology and Therapeutics**: 25(10), pp. 1135–1151.
- Chang KC, Leung CC, Yew WW, Lau TY, Tam CM. Hepatotoxicity of pyrazinamide: cohort and case-control analyses. *Am J Respir Crit Care Med*. 2008 Jun 15;177(12):1391–6.
- Cheung YM., Van K., Lan L., Barmanray R., Qian SY., Shi WY., Wong JLA., Hamblin PS., Colman PG., Topliss DJ., Denholm JT., Grossman M., 2019. Hypothyroidism associated with therapy for multi-drug resistant tuberculosis in Australia. **Intern Med J**. Mar; 49 (3): 364-372.
- Chen M, Suzuki A, Borlak J, Andrade RJ, Lucena MI, 2015. Review Drug-induced liver injury: Interactions between drug properties and host factors. **J Hepatol**: 63(2):503– 514
- Chirag M Lakhani, 2019. HHS Public Access’, *Physiology & behavior*, 176(3), pp. 139–148.
- Col AC, A., Lt Col, S., Lt Col, P. and Lt Col, P., 2012. Risk factors revealed for anti-tuberculosis drug hepatotoxicity. *Springer Healthcare News*, 1(1).
- Coleman CI, Spencer JV, Chung JO, Reddy P. Possible gatifloxacin-induced fulminant hepatic failure. *Ann Pharmacother* 2002;36:1162–116
- Curry International Tuberculosis Center. **Drug-Resistant Tuberculosis: A Survival Guide for Clinicians, Third Edition**. CITC, Washington, DC 2016. http://www.currytbcenter.ucsf.edu/sites/default/files/tb_sg3_book.pdf (Accessed on July 12, 2016).
- De Bus, L., 2010. Severe Drug-induced Liver Injury Associated with Prolonged Use of Linezolid’, **Journal of Medical Toxicology**, 6(3),
- D. Drucker, M.C. Eggo, I.E. Salit, G.N. Burrow, 1984. Ethionamide induced goitrous hypothyroidism, *Ann. Intern. Med*: 100 pp 837–839.
- Eleanor, and J. E. V. K. J. S. C. T. D. and Cegielski, P. 2013. Epidemiology of pyrazinamide-

- resistant tuberculosis in the United States, **Physiology & behavior**, 176(1), pp. 1081–1093.
- Engler H. TA., Luthy C., Dorris M.L., 1983. Reversible and irreversible inhibition of thyroid peroxidase - catalyzed iodination by thioureylene drugs. **Endocrinology**; 112 (1): 86-95.
- Falzon, D. et al., 2017. World Health Organization treatment guidelines for drug-resistant tuberculosis, 2016 update. **European Respiratory Journal**, 49 (3), p. 1602308.
- Fatmawati Umi, Kusmiati Tutik, 2017. Characteristics and the Side Effects of New MDR-TB Treatment in the Dr. Soetomo Hospital during 2016, **Jurnal Respirasi (JR)** Vol.3 No.3 Mei 2017 pp 35-41.
- Garber J.R., Cobin R.H., Gharib H., Hennessey J.V., Klein I., et al., 2012. Clinical practice guidelines for hypothyroidism in adults: cosponsored by *the American Association of Clinical Endocrinologists and the American Thyroid Association*. **Thyroid** 22(12): 1200-1235.
- García-Cortés, M., Lucena, M., Pachkoria, K., Borraz, Y., Hidalgo, R. And Andrade, R., 2008. Evaluation of Naranjo Adverse Drug Reactions Probability Scale in causality assessment of drug-induced liver injury. **Alimentary Pharmacology & Therapeutics**, 27(9), pp.780-789.
- Gaude, G., Chaudhury, A. and Hattiholi, J., 2015. Drug-induced hepatitis and the risk factors for liver injury in pulmonary tuberculosis patients. *Journal of Family Medicine and Primary Care*, 4(2), p.238.
- Gilman, A. S. P. L.-L. L. H. R. and Zhang, S. S. M. C. A. Y., 1997. Characterization of pncA Mutations in Pyrazinamide-Resistant Mycobacterium tuberculosis. **Antimicrobial Agents and Chemotherapy**, 41(3), pp. 540–543.
- Goodman & Gilman, 2012. **Dasar Farmakologi Terapi, Edisi 10**, Editor Joel. G. Hardman & Lee E. Limbird, Konsultan Editor Alfred Goodman Gilman, Diterjemahkan oleh Tim Alih Bahasa Sekolah Farmasi ITB, Penerbit Buku Kedokteran EGC, Jakarta.
- Gumbo, T., 2007. Isoniazid's Bactericidal Activity Ceases because of the Emergence of Resistance, Not Depletion of Mycobacterium tuberculosis in the Log Phase of Growth. **The Journal of Infectious Diseases**, 195(2), pp. 194–201.
- Gupta J. B.R, Milburn H.J., 2012. Drug-induced hypothyroidism in patients receiving treatment for multidrug-resistant tuberculosis in the UK. **The International Journal of Tuberculosis and Lung Disease: the official journal of the International Union against Tuberculosis and Lung Disease**; 16 (9): 1278.

- Hasan MM, Akbar SMFZ, Mahtab MA. Textbook of Hepato-Gastroenterology. Health Science Publisher. 2015;52:2463–2471.
- Honore, N. and Cole, S. T., 1994. Streptomycin resistance in mycobacteria. **Antimicrobial Agents and Chemotherapy**, 38(2), pp. 238–242.
- Huang YS, Chern HD, Su WJ, et al. Polymorphism of the N-acetyltransferase 2 gene as a susceptibility risk factor for antituberculosis drug-induced hepatitis. *Hepatology*. 2002;35:883–889.
- Jeong I, Park J-S, Cho Y-J, Yoon H Il, Song J, Lee C-T, et al. Drug induced hepatotoxicity of anti-tuberculosis drugs and their serum levels. **J Korean Med Sci**. 2015 Feb;30(2):167–72.
- Kahn JB. Latest industry information on the safety profile of levofloxacin in the US. *Chemotherapy* 2001;47:32–3
- Kemenkes, 2014. *Pedoman Nasional Pengendalian Tuberkulosis*. **Jakarta**: Depkes RI.
- Kemenkes, 2019. Panduan Pelayanan Tuberkulosis Resistan Obat untuk Fasilitas Pelayanan Kesehatan, **Kementerian Kesehatan Republik Indonesia dan Gerakan Masyarakat Hidup Sehat: Edisi 3** April 2019.
- Keshavjee, S., Gelmanova, I., Shin, S., Mishustin, S., Andreev, Y., Atwood, S., Furin, J. and Miller, A., 2012. Hepatotoxicity during treatment for multidrug-resistant tuberculosis: occurrence, management and outcome. **The International Journal of Tuberculosis and Lung Disease**, 16(5), pp.596-603.
- Kingston, K., 2018. Shoulder adhesive capsulitis: epidemiology and predictors of surgery’, *Journal of Shoulder and Elbow Surgery*. **Elsevier Inc**: 27(8), pp. 1437–1443.
- Latief, M., Dar, W., Sofi, N., Dar, I., Kasana, B., Hussain, M., Arshad, F., Shah, B. and Koul, P., 2017. Novel risk factors and early detection of anti-tubercular treatment induced liver injury—Looking beyond American Thoracic Society Guidelines. *Indian Journal of Tuberculosis*, 64(1), pp.26-32.
- Marzuki OA, Fauzi AR, Ayoub S, dkk. Prevalence and risk factors of anti-tuberculous drug induced hepatitis in Malaysia. **Singapore Med J**. 2008;49(9):688–693.
- Matveyeva S.L., Shevchenko O.S., Pogorelova O.O., 2017. The function of the thyroid gland in patients with multi-drug resistant tuberculosis. **Antimicrobial Resistance and Infection Control**: 6:82, pp 1-3.

- McDonnell M.E., Braverman L.E., Bernardo J., 2005. Hypothyroidism due to ethionamide. **N Engl J Med** 352(26): 2757-2759.
- Millard P, Wilcosky T, Reade-Christopher S, et al. Isoniazid-related fatal hepatitis. **West J Med** 1996; 164: 486–491
- Miljkovic, M., Dobric, S. and Dragojevic-Simic, V., 2011. Accuracy and reproducibility of two scales in causality assessment of unexpected hepatotoxicity. **Journal of Clinical Pharmacy and Therapeutics**: 37(2), pp.196-203.
- Mitchell J, Zimmerman H, Ishak K, et al. Isoniazid liver injury: clinical spectrum, pathology and probable pathogenesis. **Ann Intern Med** 1976; 84: 181–192.
- Modongo C., Zetola N.M., 2012. Prevalence of hypothyroidism among MDR-TB patients in Botswana. **Int J Tuberc Lung Dis** 16(11): 1561-1562.
- Munivenkatappa S., Anil S., Naik B., Volkmann T., Sagili K.D., Akshatha J.S., et al., 2016. Drug-Induced Hypothyroidism during Anti-Tuberculosis Treatment of Multidrug-Resistant Tuberculosis: Notes from the Field. **Journal of tuberculosis research**; 4 (3): 105-10.
- Mohajeri, S. A. B. I. S. J. S. H. M. A. F. and P, 2017. Evaluation of GeneXpert MTB/RIF for determination of rifampicin resistance among new tuberculosis cases in west and northwest Iran, **New Microbe and New Infect**: 19, pp. 117–120.
- Nahid, P., 2016. Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis. **Clinical Infectious Diseases**, 63(7), pp. e147–e195.
- Nair, J., 1993. The rpsL gene and streptomycin resistance in single and multiple drug-resistant strains of Mycobacterium tuberculosis. **Molecular Microbiology** 10(3), pp. 521–527.
- Naqvi, I., Mahmood, K., Talib, A. and Mahmood, A., 2015. Antituberculosis Drug-Induced Liver Injury: An Ignored Fact, Assessment of Frequency, Patterns, Severity and Risk Factors. *Open Journal of Gastroenterology*, 05(12), pp.173-184.
- Nash, K. A., Gaytan, A. and Inderlied, C. B. 1997. Detection of Rifampin Resistance in Mycobacterium tuberculosis by Use of a Rapid, Simple, and Specific RNA/RNA Mismatch Assay. **The Journal of Infectious Diseases**: 176(2), pp. 533–536. d
- Pasipanodya, J. G., Srivastava, S. and Gumbo, T., 2012. Meta-analysis of clinical studies supports the pharmacokinetic variability hypothesis for acquired drug resistance and failure of antituberculosis therapy. **Clinical Infectious Diseases**, 55(2), pp. 169–177.

- Ramappa, V. and Aithal, G. P., 2013. Hepatotoxicity Related to Anti-tuberculosis Drugs: Mechanisms and Management. **Journal of Clinical and Experimental Hepatology**. Elsevier Ltd, 3(1), pp. 37–49.
- Rozwarski, D. A., 1998. Modification of the NADH of the isoniazid target (InhA) from *Mycobacterium tuberculosis*. **Science**, 279(5347), pp. 98–102.
- Satti H., Mafukidze A., Jooste P.L., McLaughlin M.M., Farmer P.E., Seung K.J., 2012. High rate of hypothyroidism among patients treated for multidrug-resistant tuberculosis in Lesotho. **Int. J. Tuberc. Lung Dis**: 16 pp 468–472.
- Soedarsono, S., Mandayani, S., Prayuni, K. and Yuliwulandari, R., 2018. The Risk Factors for Drug Induced Hepatitis In Pulmonary Tuberculosis Patients In Dr. Soetomo Hospital. *Indonesian Journal of Tropical and Infectious Disease*, 7(3), p.73.
- Schaberg T, Rebhan K,n1996. Risk factors for side-effects of isoniazid, rifampin and pyrazinamide in patients hospitalized for pulmonary tuberculosis. **Eur. Respir. J.**; 9: 2026
- Stricker B. Drug-induced hepatic injury. 2nd ed. Amsterdam, The Netherlands: **Elsevier**, 1995: pp 237–247.
- Tostmann, A., 2008. Antituberculosis drug-induced hepatotoxicity : Concise up-to-date review', 23, pp. 192–202.
- T.Q. Jacobs, A. Ross, 2012. Adverse effects profile of multidrugresistant tuberculosis treatment, **S. Afr. Family Pract.** 54 (6) pp 531–539.
- Verma S, Kaplowitz N. Hepatotoxicity of Antitubercular Drugs. In: drug-induced liver disease. 3rd ed. **Los Angeles: Elsevier Inc.**; 2013. h. 483–499.
- Vilcheze, C. and R., J. W. 2014. Resistance to Isoniazid and Ethionamide in *Mycobacterium tuberculosis*: Genes, Mutations, and Causalities. **Microbiol Spectr**, 2(4), pp. 139–148.
- Vuppalanchi R, Chalasani N. Risk Factors for DrugInduced Liver Disease. Chapter 16. 3rd Edition. Kaplowitz N, Leve LD. **Elsevier Inc.**; 2013. 265-274.
- Wang PY, Xie SY, Hao Q, et al. NAT2 polymorphisms and susceptibility to anti-tuberculosis drug-induced liver injury: a meta-analysis. **Int J Tuberc Lung Dis**. 2012;16:589–595.
- WHO¹, 2018. **Global Tuberculosis Report 2018**, Geneva: World Health Organization.
- WHO², 2018. **Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries: Indonesia**, Geneva: World Health Organization, www.who.int/tb/data.

- WHO², 2019. **WHO Consolidated Guidelines on Drug-resistant Tuberculosis Treatment, Switzerland:** World Health Organization.
- Yee D, Valiquette C, Pelletier M, Parisien I, Rocher I, Menzies D. Incidence of serious side effects from first-line antituberculosis drugs among patients treated for active tuberculosis. *Am. J. Respir. Crit Care Med*: 167: 1472–7.
- Younossian AB, Rochat T, Ketterer JP, Wacker J, Janssens JP 2005. High hepatotoxicity of pyrazinamide and ethambutol for treatment of latent tuberculosis. *Eur. Respir. J.* 26: 462–4.
- Zhang Y, Heym B, Allen B, Young D, C. S. 1992. The catalase-peroxidase gene and isoniazid resistance of *Mycobacterium tuberculosis*. *Nature*, 359, pp. 710–713.
- Zignol, M., 2016. Special Report Twenty Years of Global Surveillance of Antituberculosis-Drug Resistance., pp. 1081–1089.
- Zuiga, J., 2012. Cellular and humoral mechanisms involved in the control of tuberculosis’, *Clinical and Developmental Immunology*, 2012